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Adipose tissue plays an essential role in metabolic homeo-
stasis. Abnormal expansion of (obesity) and markedly re-
duced (lipodystrophy) adipose tissue mass represent the
extreme opposite ends of the adiposity spectrum. Intriguingly,
both lead to metabolic dysfunction including insulin resis-
tance and type 2 diabetes. Furthermore, adipose tissue is today
recognised as an important endocrine organ and dysregulated
secretion of adipokines may lead to profound changes in
insulin sensitivity.
In the current issue of Diabetologia, Gealekman et al
present evidence that targeting adipose tissue angiogenesis
may promote insulin sensitivity (Fig. 1a) [1]. The primary
function of adipose tissue is to store energy in the form of
lipids in situations of energy excess, and release it when
energy is needed. Problems occur when the lipid storage
capacity of adipose tissue is exceeded, which leads to ectopic
deposition of lipids in insulin-sensitive tissues, including liver
and muscle. The central role of adipose tissue in whole-body
energy homeostasis makes it an attractive potential therapeutic
target. However, because it is involved in a vast array of
physiological processes throughout the body, adipose tissue
is also a challenging target.
Unlike most other adult tissues, adipose tissue displays
plasticity and has an enormous capacity to expand and
regress throughout our lifetime. Expansion of adipose tissue
requires coordinated cellular processes, including an in-
crease in volume and/or number of fat cells and alterations
in the surrounding matrix and vascularisation. Indeed, re-
cent evidence from mice with a targeted deletion of Fgf1
indicates that a failure of the ability of adipose tissue to
expand and contract in response to metabolic demands leads
to metabolic disease [2]. Adipose tissue angiogenesis (i.e.
growth of new blood vessels) ensures delivery of oxygen
and nutrients, growth factors, hormones, stem cells and
immune cells, as well as removal of waste products and
transportation of fatty acids and adipokines into the circu-
lation [3]. Thus, adipogenesis and angiogenesis are two
closely related processes. A low angiogenic capacity could
decrease adipogenic potential and consequently lead to
adipocyte hypertrophy, which, in turn, is closely related
to insulin resistance. Adipocytes themselves produce sev-
eral angiogenic factors, including leptin, vascular endothe-
lial growth factor A (VEGFA) and TNF-α. Conversely,
angiogenic factors such as VEGFA can modulate adipocyte
differentiation [3].
When adipose tissue expansion exceeds compensatory
vascular supply, hypoxia may develop. Local adipose tissue
hypoxia has been proposed as a mechanism leading to
dysregulation of adipose tissue function in the context of
obesity and insulin resistance [3]. Thus, improving angiogen-
esis may be a novel approach to tackle adipose tissue hypoxia
and hence promote insulin sensitivity. However, in contrast
to most rodent models of obesity implicating adipose
tissue hypoxia as a factor inducing adipose tissue dysfunc-
tion, a recent report indicates that in obese insulin-resistant
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individuals there is adipose tissue hyperoxia. The hyperoxia is
present despite lower adipose tissue blood flow, possibly due
to lower oxygen consumption by obese adipose tissue [4].
Anti-angiogenic drugs are being used as first-line treatment
for various cancers. Like tumours, adipose tissue depends on
proper vascularisation to grow, and so inhibition of adipose
tissue angiogenesis may inhibit adipose tissue expansion and
thus the development of obesity. Indeed, systemic administra-
tion of anti-angiogenic agents in different mouse obesity
models has shown promising results, including dose-
dependent weight reduction and loss of fat mass (Fig. 1b) [3,
5]. This was, however, partly explained by reduced food
intake [3]. Furthermore, inhibition of adipose tissue expansion
achieved by reducing adipose tissue vascularisation might
lead to lipotoxicity because of increased lipolysis and/or ec-
topic fat deposition, particularly if energy intake is not simul-
taneously decreased. Furthermore, inhibition of angiogenesis
may have adverse effects in metabolically active brown adi-
pose tissue, which may, in turn, lower energy expenditure.
Impaired adipose tissue angiogenesis could potentially
limit adipogenesis and thereby contribute to metabolic dys-
function by promoting ectopic lipid accumulation [6]. Thus,
the converse approach, i.e. enhancing adipose tissue angio-
genesis, preferably in the subcutaneous depot, should promote
fat storage in the appropriate tissue and subsequently protect
against metabolic dysfunction. One of the few groups of
therapeutic agents to directly target adipose tissue is the thia-
zolidinediones (TZDs, e.g. rosiglitazone), a class of peroxi-
some proliferator-activated receptor γ (PPARγ) agonists.
These drugs improve insulin sensitivity by promoting adipo-
genesis and fatty acid uptake in adipose tissue and thereby
sequester lipids away from non-fat tissues. Consequently,
metabolic function is improved despite increased fat mass by
an increase in the amount of subcutaneous fat and a decrease
in the amount of visceral fat [7]. In the current issue of
Diabetologia, Gealekman et al report that short-term treatment
(6 weeks) with rosiglitazone in overweight and obese individ-
uals results in alterations in adipose tissue architecture in terms
of increased formation of small adipocytes and increased
capillary density (Fig. 1a) [1]. The authors suggest that the
improved adipose tissue vascularisation may in part mediate
the therapeutic actions of rosiglitazone and that adipose tissue
vascularisation can directly be modulated by PPARγ activa-
tion. The same research group has previously reported a
correlation between angiogenic capacity in subcutaneous ad-
ipose tissue and insulin sensitivity assessed by HOMA of
insulin resistance (HOMA-IR) [6]. Intriguingly, in the present
study, the improved TZD-induced adipose tissue vascularisa-
tion was not accompanied by an improvement in HOMA-IR.
This might partly be explained by the fact that only volunteers
with normal glucose tolerance were included in the study.
TZDs are known to alter the production of adipokines
(for example, increased adiponectin and reduced TNF-α and
leptin). In accordance with previous studies, Gealekman et
al observed increased circulating adiponectin levels in response
to rosiglitazone treatment [1]. Adiponectin levels were positive-
ly correlated with capillary growth rate. Adiponectin has been
shown to have both anti- and pro-angiogenic activity, making it
difficult to interpret its role in adipose tissue angiogenesis
and involvement in rosiglitazone-induced vascularisation.
The VEGF system is considered to be responsible for the
majority of angiogenic activity in adipose tissue [3]. Over-
expression of Vegfa specifically in adipose tissue of diet-
induced obese mice results in enhanced vascularisation and
browning of adipose tissue accompanied with improved insu-
lin sensitivity and higher energy expenditure [5]. Consistent













Fig. 1 Proposed mechanisms whereby enhancing (a) or inhibiting (b)
adipose tissue (AT) angiogenesis leads to increased insulin sensitivity.
(a) Outline of approached presented in [1, 8]. Green boxes denote
inferred favourable effects, while red boxes indicate possible detrimen-
tal side-effects. AT, adipose tissue; BAT, brown adipose tissue; EE,
energy expenditure
Diabetologia (2012) 55:2562–2564 2563
with the present study, Gealekman et al previously reported
smaller fat cells and increased capillary density following
rosiglitazone treatment in obese and diabetic rodents [8].
The angiogenic effect of rosiglitazone in rodents was partly
attributed to increased Vegfa expression and angiopoietin-
related protein 4 production [8]. Unfortunately, the expression
of angiogenic factors was not evaluated in the present study. In
contrast to these studies, rosiglitazone has been shown to have
anti-angiogenic effects leading to suppression of primary tu-
mour growth and metastasis [9]. Notably, rosiglitazone has
been withdrawn from the market owing to an increased risk of
cardiovascular events, which makes the reported results chal-
lenging to translate to the clinical situation.
Maintaining adequate function in expanding adipose tissue
is dependent on angiogenesis, and adipose tissue mass can
thus be regulated through the vasculature. TZDs improve
insulin sensitivity despite paradoxically increasing fat mass.
The paper in the current issue of Diabetologia [1], suggests
that one mechanism by which TZDs improve insulin resis-
tance is by stimulating angiogenesis, thereby promoting adi-
pogenesis in subcutaneous adipose tissue (Fig. 1a).
The relationship between adipose tissue vascularisation and
obesity in humans remains to be established. Some reports
indicate lower vascular density with increasing BMI [4, 6, 10],
while others note the opposite [11]. This discrepancy may be
explained at least in part by heterogeneity in the study popula-
tions, such as different stages of obesity and insulin sensitivity.
Furthermore, Gealekman et al have previously examined angio-
genic capacity and capillary density in different adipose tissue
depots, and report that subcutanous adipose tissue has a higher
capillary density than visceral adipose tissue [6].
Due to the paucity of preclinical and clinical studies, it is
difficult to draw firm conclusions as to whether angiogenic medi-
atorsmay be a fruitful approach to regulate adipose tissue function
and mass (Fig. 1). Furthermore, current reports demonstrate im-
proved metabolic function in response to either enhancing or
inhibiting adipose tissue angiogenesis [3, 5, 8]. This paradox
highlights the complexity of interfering with adipose tissue angio-
genesis (as well as possible off-target effects), and it is uncertain
whether stimulation or inhibition of adipose tissue angiogenesis is
preferable (Fig. 1).While some obesity-related complicationsmay
benefit from inhibition of adipose tissue angiogenesis (e.g. type 2
diabetes, inflammation and cancer), others may benefit from
stimulation of adipose tissue angiogenesis (e.g. hypertension and
cardiovascular diseases) [3]. Tissues that are highly metabolically
active, such as brown adipose tissue, may derive an advantage
from increased angiogenesis by increasing energy expenditure. If
and when we see the advent of angiogenic modulators as a
treatment of obesity and related metabolic disorders, they clearly
need to be tissue-specific. Since adipose tissue is one of the
largest organs in the body, high doses of angiogenic modula-
tors may be required to target this tissue, and consequently the
risk of side effects is high. Nonetheless, modulation of adipose
angiogenesis remains an intriguing approach to improve in-
sulin sensitivity in the context of metabolic disease.
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